retatrutide vs tirzepatide trial Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Retatrutide vs Tirzepatide for Obesity
Pay in 4 interest-free payments of $5.70 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1











00243-1/asset/23df9500-d21e-4a61-9bfa-1536b8dc9f75/main.assets/gr4a_lrg.jpg)













